Ossiam Decreases Holdings in Bristol-Myers Squibb (NYSE:BMY)

Ossiam reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 17.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 49,633 shares of the biopharmaceutical company's stock after selling 10,336 shares during the period. Ossiam's holdings in Bristol-Myers Squibb were worth $2,807,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in BMY. Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $28,000. Comprehensive Financial Planning Inc. PA bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $34,000. Westend Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $38,000. Tacita Capital Inc bought a new stake in Bristol-Myers Squibb in the fourth quarter worth approximately $39,000. Finally, M Holdings Securities Inc. bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $39,000. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded down $1.32 during midday trading on Wednesday, hitting $48.50. The company's stock had a trading volume of 24,030,177 shares, compared to its average volume of 13,058,887. The stock has a fifty day moving average price of $56.71 and a 200 day moving average price of $56.59. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The firm has a market capitalization of $98.69 billion, a price-to-earnings ratio of -10.97, a P/E/G ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.11%. Bristol-Myers Squibb's payout ratio is currently -56.11%.

Analyst Ratings Changes

BMY has been the topic of several research analyst reports. Wells Fargo & Company increased their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Piper Sandler assumed coverage on Bristol-Myers Squibb in a report on Tuesday. They issued an "overweight" rating and a $65.00 price target on the stock. UBS Group decreased their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Citigroup raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the business's stock in a transaction dated Friday, February 14th. The stock was bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.